State Street SPDR S&P Pharmaceuticals ETF XPH
63.47 USD -1.89 (-2.89%)
Nov 5, 2026, 1:28 PM EST
63.19 Day range 66.23
48.30 52-week range 74.06
- YTD
- +13.32%
- 1 year
- +30.49%
- Market cap
- 263.59M
- EPS (ttm)
- 3.87
- P/E ratio
- 16.39
- YTD return
- +13.32%
- 1-year return
- +30.49%
- Volume
- 77.38K
- Avg volume
- 187.89K
- Open
- 65.85
- Previous close
- 65.36
- Day's range
- 63.19 – 66.23
- 52-week range
- 48.30 – 74.06
5m -0.39 (-0.59%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 45.94
- 200-day average
- 42.92
About State Street SPDR S&P Pharmaceuticals ETF
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
News
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF 
Which Healthcare ETF Is the Better Buy: State Street's Pharma XPH or Simplify's Mission-Driven PINK? 
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now? 
XPH: Healthcare Sector Dashboard For October 
Better Pharma ETF: iShares IHE vs. State Street XPH 
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma 
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)? 
Execution of Pharma Tariffs Brings These ETFs Into Focus 
SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Sees Large Volume Increase – Still a Buy? 
Integrated Wealth Concepts LLC Buys Shares of 48,874 SPDR S&P Pharmaceuticals ETF $XPH
Your note
Sign in to keep a note on XPH — it syncs with the Stock Master app.